The combination of increasingly vocal politicians railing against US drug pricing, a weak global recovery, uncertainties created by Brexit, and the outcome of the US presidential race have all coalesced to create uncertainty for investors. However, for those willing to take a longer-term view, the outlook is more nuanced, with a projected compound annual growth rate of 6.3 percent in global prescription sales over the next six years according to the EvaluatePharma World Preview 2016, Outlook to 2022 report from life science market intelligence firm, Evaluate Ltd.
The annual report, which sets the industry standard for consensus forecasts for the life science industry, provides an overview of the sector including key trends in prescription drug sales, patent risk, global brand sales, market performance by therapy area, R&D spend, pharma innovation analysis and consensus forecasts to 2022.
“Most of this projected growth is driven by a number of new products that will come onto the market in the next seven years. However, there are several issues that could spoil this rosy picture of uninterrupted growth, including political scrutiny over pricing. The recent outcry over Mylan’s price increases for EpiPen – followed by the company’s repeated capitulations – show just how sensitive pricing models can be to political pressure,” said Antonio Iervolino, Head of Forecasting, Evaluate. “As a result of this, we expect companies to continue investing in pricing models strongly tied to real world benefits and consistently incorporate pricing and market access discussions at a much earlier stage in the clinical development process. So, while currently the industry does have plenty to celebrate, there are potential brakes on progress that could make the outlook much more mixed.”
World Preview 2016 Highlights:
The “EvaluatePharma World Preview 2016, Outlook to 2022” report, based on consensus forecasts from EvaluatePharma, can be downloaded at http://www.evaluate.com/PharmaWorldPreview2016.
About Evaluate Ltd
Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data and insights, combined with personalised, expert client support. Our online subscription services cover the pharmaceutical, biotech and medtech sectors. Our Custom Services group delivers project based analytical and data services. EP Vantage, our independent, award-winning editorial team, offers data-driven, forward-looking news, commentary and analysis on a daily basis. For more information visit www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @evaluateJP, @epclinicaltrial, @epvantage.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160914005324/en/Business Wire
Last updated on: 14/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.